Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof
21.7.2022 18:00:00 EEST | Business Wire | Press release
Innovaderm’s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences’ VTAMA® (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.
Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.
“This is a great milestone for patients – one that we have been working towards for years,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof’s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.”
VTAMA® cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
“VTAMA® cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,” says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. “We appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum – from mild to severe.”
Dr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103629
For information on Innovaderm’s early to late phase study capabilities, visit our website.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information and Patient Information.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Dermavant Sciences
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005175/en/
Contact information
For more information:
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
Anna Tallman
Vice-President, Medical Affairs
Dermavant Sciences
anna.tallman@dermavant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Launches Spend Clearly AI to Help Enterprise Tech Leaders Take Control of Growing IT and AI Costs6.5.2026 23:32:00 EEST | Press release
Brightfin, a leader in AI native IT cost optimization, today announced the launch of Spend Clearly AI, an intelligent optimization app purpose-built for enterprise technology leaders navigating the dual pressures of rising IT complexity and rapidly escalating AI investment. As organizations race to deploy AI apps, models, and infrastructure, technology demands on the budget are expanding faster than ever and growing harder to track, justify, and control. The modern enterprise IT bill has become a moving target. Spend Clearly AI gives CIOs, CTOs, and IT finance teams a single, intelligent app to see exactly where every technology dollar is going, eliminate waste, and stay ahead of costs before they spiral. "Stop thinking about IT as a cost problem. The goal isn't just to spend less — the goal is to spend better," said Joel Martins, CEO of Brightfin. "When you have real visibility and can trace every technology dollar to what it's delivering, you stop cutting and start optimizing. CIOs w
iQmetrix to Showcase Intelligent Commerce Operating System and Catalyst Innovation at DTW Ignite 20266.5.2026 20:20:00 EEST | Press release
iQmetrix, the Intelligent Commerce Operating System for telecom, announced today it will exhibit, speak, and compete as a bronze sponsor at DTW Ignite 2026 in Copenhagen from June 23–25. The company will deliver a live product demo in The Loft, showcase its ODA PRISM Catalyst project alongside a consortium of global operators and technology partners, and exhibit at Booth #317 throughout the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506948390/en/ The debut marks a milestone in iQmetrix’s global growth strategy and deepens its partnership with TM Forum, following its recent recognition as an ODA Component Directory Partner. The Future of Commerce Is Won at the Orchestration Layer DTW Ignite 2026’s theme, “The Future. Faster.,” captures the urgency facing communications service providers worldwide. Telcos have spent decades building world-class networks that consumers increasingly take for granted, yet that inves
Go Beyond the Guidebook: Why Ireland Rewards Those Who Slow Down6.5.2026 19:15:00 EEST | Press release
In a world where travel often feels rushed and driven by checklists, Ireland stands apart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501313521/en/ Lusty Beg Island Kesh, Co. Fermanagh The destination offers something deeper, drawing visitors beyond the expected toward richer encounters with its landscapes, culture and communities. As a compact island, Ireland gives holiday makers the chance to take in much of the destination while still travelling at a relaxed, unhurried pace. It’s a chance to slow down, not to do less, but to feel more - more calm, more connection, and more of what makes travel meaningful. This approach to travel is matched by Ireland’s natural warmth and welcome, helping visitors feel at home from the moment they arrive. Take the scenic route From the rugged coastline of the Wild Atlantic Way, one of the world’s longest coastal routes, to the rolling landscapes of Ireland’s Hidden Heartlands, Irela
TACTICA AI Introduces Region’s First AI Platform for Mission-Critical, Real-Time Operational Decisions6.5.2026 18:18:00 EEST | Press release
TACTICA AI, an Abu Dhabi-based start-up, today introduced its multi-domain decision-support platform to a wider market during Make it in the Emirates 2026. At a time of increasing operational complexity and pressure to make faster, better-informed decisions, the platform is designed to transform fragmented intelligence, sensor, and operational data into real-time decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506006177/en/ TACTICA AI Introduces Region’s First AI Platform for Mission-Critical, Real-Time Operational Decisions (Photo: AETOSWire) Already active in operational environments, TACTICA AI is believed to be the first publicly known platform of its type developed in the region, creating a new category of operational AI that goes beyond dashboards, data feeds, and analytics tools to support decision-making at the mission layer. The underlying technology was developed by the Technology Innovation Institute
FlightSafety International Receives FAA Approval for Virtual Aircraft Preflight Inspection with Evaluation Mode6.5.2026 17:05:00 EEST | Press release
FlightSafety International Inc., the global leader in aviation training and simulation technology, today announced it has received Federal Aviation Administration (FAA) approval for Virtual Aircraft Preflight Inspection (VAPI) with Evaluation Mode for three aircraft training programs: the Embraer EMB-550, Gulfstream G500/G600, and Citation Latitude. This innovative capability allows pilots in initial training to complete a 3D virtual aircraft preflight inspection while in Training Mode, with the added ability to transition directly into the flight deck, followed by Evaluation Mode, that allows pilots to do their preflight check ride portion. “VAPI represents a meaningful advancement in training innovation,” said David Penney, VP of Safety, Courseware and Regulatory Affairs, FlightSafety International. “By leveraging an immersive 3D environment, it offers pilots a more engaging and practical way to develop aircraft familiarity, strengthen inspection discipline, and better prepare for re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom